CVS Caremark, FTC settle insulin pricing case for $13B

The FTC settled its antitrust case against CVS Caremark over insulin pricing practices, requiring the PBM to pass rebates to patients at point of sale, delink manufacturer fees from list prices, and increase transparency. The settlement is expected to deliver up to $13 billion in consumer savings over ten years. If you sell insulin or manage pharmacy benefits, the PBM rebate model that kept low-cost drugs off formularies just became illegal. You can now build products that exploit the gap between what plans pay and what patients see at checkout.